A5088732507- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Diagnosis and treatment of tuberculosis
- Infectious Diseases and Tuberculosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Cardiac electrophysiology and arrhythmias
- Pneumonia and Respiratory Infections
- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- Ion channel regulation and function
- Antimicrobial Resistance in Staphylococcus
- Neonatal and fetal brain pathology
- Hepatitis C virus research
- Healthcare cost, quality, practices
- Infectious Encephalopathies and Encephalitis
Goodwin College
2023
Liverpool School of Tropical Medicine
2022
Instituut voor Tropische Geneeskunde
2022
Mongolian University of Life Sciences
2022
Phthisiopneumology Institute "Chiril Draganiuc"
2022
MRC Clinical Trials Unit at UCL
2022
University College London
2022
Medical Research Council
2022
National Institute of Research in Tuberculosis
2022
Helen Joseph Hospital
2022
Cohort studies in Bangladesh showed promising cure rates among patients with multidrug-resistant tuberculosis who received existing drugs regimens shorter than that recommended by the World Health Organization (WHO) 2011.We conducted a phase 3 noninferiority trial participants rifampin-resistant was susceptible to fluoroquinolones and aminoglycosides. Participants were randomly assigned, 2:1 ratio, receive short regimen (9 11 months) included high-dose moxifloxacin or long (20 followed 2011...
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a acceptable side-effect profile than current needed.We conducted an open-label, phase 2-3, multicenter, randomized, controlled, noninferiority trial to evaluate the efficacy safety of three 24-week, for tuberculosis. Patients in Belarus, South Africa, Uzbekistan who were 15 years age or older had pulmonary tuberculosis enrolled. stage 2 trial, 24-week regimen bedaquiline,...
BackgroundAround 500 000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are needed. Following an interim analysis, we report the final safety efficacy TB-PRACTECAL trial, evaluating oral regimens for tuberculosis.MethodsThis open-label, randomised, controlled, multi-arm, multicentre, non-inferiority trial was conducted at seven hospital community sites in Uzbekistan, Belarus, South Africa,...
Treatment for TB is lengthy and toxic, new regimens are needed.
ABSTRACT Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on use QT-prolonging agents. Using data from randomized controlled trial, TB-PRACTECAL, we investigated differences in QTcF among participants three interventional arms: BPaL (bedaquiline, pretomanid, and linezolid), BPaLC (BPaL with clofazimine), BPaLM moxifloxacin). Additionally, assessed whether age, body mass index, country were causally associated prolongation. The trial included South Africa,...
BACKGROUND: TMC207-C211 (NCT02354014) is a Phase 2, open-label, multicentre, single-arm study to evaluate pharmacokinetics, safety/tolerability, antimycobacterial activity and dose selection of bedaquiline (BDQ) in children (birth <18 years) with multidrug-resistant-TB (MDR-TB). METHODS: Patients received 24 weeks’ BDQ an anti-MDR-TB background regimen (BR), followed by 96 weeks safety follow-up. Results the primary analysis are presented based on data up for Cohort 1 (≥12–<18 years;...
Abstract Background Stage 1 of the STREAM trial demonstrated that 9 month (Short) regimen developed in Bangladesh was non-inferior to 20 (Long) 2011 World Health Organization recommended regimen. We assess association between HIV infection and radiographic manifestations tuberculosis factors associated with time culture conversion trial. Methods Reading chest radiographs undertaken independently by two clinicians, films discordant reading were read a third reader. Recording abnormal opacity...
Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB much greater than those drug-susceptible TB, both health service patient-incurred costs. Urgent action is needed to identify short, effective, tolerable cheaper treatments people with quinolone-susceptible quinolone-resistant MDR-TB. We present protocol an economic evaluation (PRACTECAL-EE substudy) alongside ongoing clinical...
BACKGROUND: STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy a short regimen rifampicin-resistant TB (RR-TB) compared to long as recommended by the WHO. The present paper analyses factors associated with definite or probable failure relapse (FoR) event in participants receiving Short regimen.METHODS: This analysis is restricted 253 allocated and based on protocol-defined modified intention...
OBJECTIVES: To assess the performance of GenoType MTBDR sl v1, a line-probe assay (LPA), to exclude baseline resistance fluoroquinolones (FQs) and second-line injectables (SLIs) in Standard Treatment Regimen Anti-tuberculosis Drugs for Patients With MDR-TB 1 (STREAM 1) trial. METHODS: Direct sputum results site laboratories were compared indirect phenotypic drug susceptibility testing (pDST) central laboratory, with DNA sequencing as reference standard. RESULTS: Of 413 multidrug-resistant TB...
Background/Introduction: TB-PRACTECAL studied six-month, more tolerable regimens of oral drugs for rifampicin resistant tuberculosis. The PRACTECAL-PRO, a sub study, measured participants’ quality life (QoL) on treatment. Methods: We conducted sequential evaluation QoL using the Short Form 12 (SF-12) and St George’s Respiratory Questionnaire (SGRQ) at four timepoints (baseline, 12, 24, 48 weeks). Healthy age sex-matched volunteers were surveyed single timepoint to establish locally relevant...
INTRODUCTION The TB-PRACTECAL study trialed a shorter, more tolerable regimen of oral drugs than standard care (SoC) – which can last for up to 20 months and involve both injectables tablets day. In this sub-study, PRACTECAL-PRO, we measured explored trial participant quality life, experiences, perspectives on treatment, understand outcomes fully. Both studies were conducted in Uzbekistan, South Africa, Belarus. METHODS We mixed-methods evaluation using life (QoL) surveys in-depth...
No abstract available.
INTRODUCTION Rifamipcin-resistant tuberculosis (RR-TB) affects around 465,000 people each year globally. Current treatment is of 9-20 months’ duration; toxic and poorly efficacious. TB-PRACTECAL a multi-arm, 2-stage, randomised controlled, multi-country, non-inferiority trial comparing 24-week regimens to the locally approved standard care (control). We report stage 1 2 outcomes as well additional analyses from dropped arms. METHODS Participants 15 years above with pulmonary RR-TB...